Inflammatory breast cancer in Tunisia in the era of multimodality therapy

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 473-480

  Labidi, S I ^a,b   Mrad, K ^a   Mezlini, A ^a   Ayadi Ouarda, M ^a   Combes, J D ^b   Ben Abdallah, M ^a   Ben Romdhane, K ^a   Viens, P ^c   Ben Ayed, F ^a  

^a SALAH AZAIEZ INSTITUTE   (Tunisia)

^b CENTRE LÉON BÉRARD   (France)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

Hormone therapy; Inflammatory breast cancer; Multimodality therapy; Pathologic complete response; Prognostic factors; Tunisia

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; NAVELBINE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY BREAST CANCER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 40149109780     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm480     Document Type: Article

References (38)

1. P. Bonnier C. Charpin C. Lejeune Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer 62 1995 382 385
2. S. Chang S.L. Parker T. Pham Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992 Cancer 82 1998 2366 2372
3. K.W. Hance W.F. Anderson S.S. Devesa Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute J Natl Cancer Inst 97 2005 966 975
4. N. Mourali P.H. Levine F. Tabbane Rapidly progressing breast cancer (poussee evolutive) in Tunisia: studies on delayed hypersensitivity Int J Cancer 22 1978 1 3
5. P. Denoix Treatment of Malignant Breast Tumors. Recent Results in Cancer Research. No. 31 1970 Springer Berlin, Germany
6. M. Maalej H. Frikha S. Ben Salem Breast cancer in Tunisia: clinical and epidemiological study Bull Cancer 86 1999 302 306
7. N.T. Ueno A.U. Buzdar S.E. Singletary Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M.D. Anderson Cancer Center Cancer Chemother Pharmacol 40 1997 321 329
8. E.E. Harris D. Schultz H. Bertsch Ten-year outcome after combined modality therapy for inflammatory breast cancer Int J Radiat Oncol Biol Phys 55 2003 1200 1208
9. M. Ben Abdallah Epidemiology of Cancer in Tunisia. Registre de l'institut Salah Azaiz 1997 Association tunisienne de lutte contre le cancer Tunis, Tunisia 67 75
10. N. Mourali F. Tabbane L.R. Muenz Ten-year results utilizing chemotherapy as primary treatment in nonmetastatic, rapidly progressing breast cancer Cancer Invest 11 4 1993 363 370
11. N.L. Spector K. Blackwell J. Hurley EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response Proc Am Soc Clin Oncol 24 18S 2006 (Abstr 502)
12. F. Ben Ayed A. Mezlini P. Chinet-Charrot Five-year of a randomized phase III trial comparing high-dose chemotherapy plus lenogastrim support with conventional dose chemotherapy in non-metastatic, unilateral, inflammatory breast cancer patients: interim analyses Breast Cancer Res Treat 76 Suppl 1 2002 S93 (Abstr 345)
13. I.D. Fleming J.S. Cooper D.E. Henson AJCC Cancer Manual for Staging 5th edition 1997 Lippincott–Raven Philadelphia, PA
14. NCI/NHLBI Obesity Education Initiative Task Force Members Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults 1998 NHLBI Bethesda, MD
15. B. Chevallier H. Roche J.P. Olivier Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate Am J Clin Oncol 16 1993 223 228
16. W.F. Anderson C. Schairer B.E. Chen Epidemiology of inflammatory breast cancer (IBC) Breast Dis 22 2006 9 23
17. S. Chang A.U. Buzdar S.D. Hursting Inflammatory breast cancer and body mass index J Clin Oncol 16 1998 3731 3735
18. M.C. Pike D.V. Spicer L. Dahmoush Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk Epidemiol Rev 151 1993 17 35
19. N. Mokhtar J. Elati R. Chabir Diet culture and obesity in northern Africa J Nutr 131 2001 887S 892S
20. F. Ben Ayed H. Abaza S. Khalfallah Breast cancer in patients under 35 years of age Proc Am Soc Clin Oncol 21 2002 (Abstr 276)
21. C Schairer A Soliman H Khaled. Clinical characteristics of inflammatory breast cancer in Egypt and Tunisia: a case series (submitted)
22. P. Bonnier S. Romain J.M. Dilhuydy Influence of pregnancy on the outcome of breast cancer: a case-control study Int J Cancer 72 1997 720 727
23. N. Mourali L.R. Muenz F. Tabbane Epidemiologic features of rapidely progressing breast cancer in Tunisia Cancer 46 1980 2741 2746
24. R.R. Applewhite L.R. Smith F. DiVencenti Carcinoma of the breast associated with pregnancy and lactation Am Surg 39 1973 101 104
25. G. Bonadonna M. Zambetti P. Valagussa Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results JAMA 273 1995 542 547
26. C. Veyret C. Levy P. Chollet Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial Cancer 19 3 2006 473 480
27. P. Therasse L. Mauriac M. Welnicka-Jaskiewicz Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study J Clin Oncol 21 5 2003 843 850
28. M. Cristofanilli A.M. Gonzalez-Angulo A.U. Buzdar Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D. Anderson Cancer Center experience Clin Breast Cancer 4 2004 415 419
29. M. Cristofanilli A.U. Bzdar N. Sneige Paclitaxel in the multimodality treatment for inflammatory breast cancer Cancer 92 2001 1775 1782
30. E.R. Fisher J. Wang J. Bryant Pathobiology of preoperative chemotherapy Cancer 95 2002 681 695
31. F. Bertucci C. Tarpin E. Charaffe-Jaufret Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment Bone Marrow Transplant 33 2004 913 920
32. G. Somlo P. Frankel W. Chow Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy J Clin Oncol 22 2004 1839 1848
33. B. Arun R. Slack E. Gehan Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma Cancer 85 1999 93 99
34. C.A. Perez J.N. Fields P.M. Fracasso Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma Cancer 74 Suppl 2 1994 466 476
35. J.A. Low A.W. Berman S.M. Steinberg Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy J Clin Oncol 22 2004 4067 4074
36. J. Attia-Sobol J.P. Ferrier H. Cure Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis Eur J Cancer 29A 1993 1081 1088
37. R. Jakesz An update on ovarian suppression/ablation Int J Gynecol Cancer 16 Suppl 2 2006 511 514
38. Early Breast Cancer Trialist's Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717